ARNA

Arena Pharmaceuticals, Inc. Press Releases

$4.77
*  
0.06
1.27%
Get ARNA Alerts
*Delayed - data as of Jul. 30, 2014  -  Find a broker to begin trading ARNA now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    ARNA After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity
7/30/2014 8:00:00 AM - PR Newswire

Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category
7/29/2014 8:00:00 AM - PR Newswire

Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1
7/25/2014 8:00:00 AM - PR Newswire

Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in Israel
7/21/2014 8:00:00 AM - PR Newswire

Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office
7/15/2014 4:31:00 PM - PR Newswire

Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales Force for BELVIQ® (lorcaserin HCl) CIV
7/10/2014 8:00:00 AM - PR Newswire

Pre-market Equity Watch on Biotech Industry -- Research on Halozyme Therapeutics, XOMA, Amicus Therapeutics, and Arena Pharma
7/10/2014 7:20:00 AM - PR Newswire

Arena Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference
6/13/2014 8:00:00 AM - PR Newswire

Lorcaserin HCl Data to be Presented at American Diabetes Association's 74th Scientific Sessions
6/9/2014 7:55:00 AM - PR Newswire

Arena Pharmaceuticals Initiates Phase 1b Clinical Trial of APD334 for Autoimmune Diseases
6/3/2014 8:00:00 AM - PR Newswire

Technical Coverage on Health Care Sector Equities -- Research on Arena Pharma, Exelixis, Dendreon, and Seattle Genetics
5/30/2014 7:40:00 AM - PR Newswire

Arena Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
5/27/2014 8:00:00 AM - PR Newswire

Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2014 Financial Results
5/12/2014 4:03:00 PM - PR Newswire

Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ® (lorcaserin HCl) CIV by 50%
5/9/2014 8:00:00 AM - PR Newswire

Active Stocks Technical Review -- Research on Arena Pharma, Yamana Gold, Avon Products, and Banco Bradesco
5/5/2014 8:54:00 AM - PR Newswire

Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, May 12
5/5/2014 8:00:00 AM - PR Newswire